Heterobivalent agents targeting PSMA and integrin- αvβ3

Bioconjugate Chemistry

Volumn 25, Issue 2, 2014, Pages 393-405

  Shallal, Hassan M ^a   Minn, Il ^a   Banerjee, Sangeeta R ^a   Lisok, Ala ^a   Mease, Ronnie C ^a   Pomper, Martin G ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; DISEASES; PROBES;

IMAGING AGENT; IN-VITRO; INTEGRINS; MALIGNANT CELLS; PROSTATE-SPECIFIC MEMBRANE ANTIGENS; SELECTIVE IMAGING; SURFACE PROTEINS; TARGETED IMAGING; TETRAACETIC ACID; THERAPEUTIC AGENTS;

TUMORS;

CONTRAST MEDIUM; HETEROBIVALENT AGENT; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TETRAXETAN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER TISSUE; CONFORMATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG TARGETING; EX VIVO STUDY; FLUORESCENCE IMAGING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; TUMOR XENOGRAFT;

ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; INTEGRIN ALPHAVBETA3;

EID: 84894421482     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc4005377     Document Type: Article

References (50)

1. Yang, S. Y., Adelstein, J., and Kassis, A. I. (2010) Putative molecular signatures for the imaging of prostate cancer Expert Rev. Mol. Diagn. 10, 65-74
2. Mehra, N. K., Mishra, V., and Jain, N. K. (2013) Receptor-based targeting of therapeutics Ther. Delivery 4, 369-94
3. Winnard, P. T., Jr., Pathak, A. P., Dhara, S., Cho, S. Y., Raman, V., and Pomper, M. G. (2008) Molecular imaging of metastatic potential J. Nucl. Med. 49 (Suppl 2) 96S-112S
4. Barrett, J. A., Coleman, R. E., Goldsmith, S. J., Vallabhajosula, S., Petry, N. A., Cho, S., Armor, T., Stubbs, J. B., Maresca, K. P., Stabin, M. G., Joyal, J. L., Eckelman, W. C., and Babich, J. W. (2013) First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer J. Nucl. Med. 54, 380-7
5. Cho, S. Y., Gage, K. L., Mease, R. C., Senthamizhchelvan, S., Holt, D. P., Jeffrey-Kwanisai, A., Endres, C. J., Dannals, R. F., Sgouros, G., Lodge, M., Eisenberger, M. A., Rodriguez, R., Carducci, M. A., Rojas, C., Slusher, B. S., Kozikowski, A. P., and Pomper, M. G. (2012) Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer J. Nucl. Med. 53, 1883-91
6. Miyamoto, D. T., Lee, R. J., Stott, S. L., Ting, D. T., Wittner, B. S., Ulman, M., Smas, M. E., Lord, J. B., Brannigan, B. W., Trautwein, J., Bander, N. H., Wu, C. L., Sequist, L. V., Smith, M. R., Ramaswamy, S., Toner, M., Maheswaran, S., and Haber, D. A. (2012) Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer Cancer Discovery 2, 995-1003
7. Taylor, R. M., Severns, V., Brown, D. C., Bisoffi, M., and Sillerud, L. O. (2012) Prostate cancer targeting motifs: expression of alphanu beta3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts Prostate 72, 523-32
8. Wei, D., Jiang, X., Zhou, L., Chen, J., Chen, Z., He, C., Yang, K., Liu, Y., Pei, J., and Lai, L. (2008) Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching J. Med. Chem. 51, 7882-8
9. Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., and Bender, A. (2011) From in silico target prediction to multi-target drug design: current databases, methods and applications J Proteomics 74, 2554-74
10. Speck-Planche, A., Kleandrova, V. V., Luan, F., and Cordeiro, M. N. (2011) Multi-target drug discovery in anti-cancer therapy: fragment-based approach toward the design of potent and versatile anti-prostate cancer agents Bioorg. Med. Chem. 19, 6239-44
11. Roth, B. L., Sheffler, D. J., and Kroeze, W. K. (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discovery 3, 353-9
12. Josan, J. S., Handl, H. L., Sankaranarayanan, R., Xu, L., Lynch, R. M., Vagner, J., Mash, E. A., Hruby, V. J., and Gillies, R. J. (2011) Cell-specific targeting by heterobivalent ligands Bioconjugate Chem. 22, 1270-8
13. Xu, L., Josan, J. S., Vagner, J., Caplan, M. R., Hruby, V. J., Mash, E. A., Lynch, R. M., Morse, D. L., and Gillies, R. J. (2012) Heterobivalent ligands target cell-surface receptor combinations in vivo Proc. Natl. Acad. Sci. U. S. A. 109, 21295-300
14. Li, Z. B., Wu, Z., Chen, K., Ryu, E. K., and Chen, X. (2008) 18F-labeled BBN-RGD heterodimer for prostate cancer imaging J. Nucl. Med. 49, 453-61
15. Liu, Z., Niu, G., Wang, F., and Chen, X. (2009) (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging Eur. J. Nucl. Med. Mol. Imaging 36, 1483-94
16. Yan, Y., Chen, K., Yang, M., Sun, X., Liu, S., and Chen, X. (2011) A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging Amino Acids 41, 439-47
17. Bouchelouche, K., Choyke, P. L., and Capala, J. (2010) Prostate specific membrane antigen- a target for imaging and therapy with radionuclides Discovery Med. 9, 55-61
18. Foss, C. A., Mease, R. C., Cho, S. Y., Kim, H. J., and Pomper, M. G. (2012) GCPII imaging and cancer Curr. Med. Chem. 19, 1346-59
19. Osborne, J. R., Akhtar, N. H., Vallabhajosula, S., Anand, A., Deh, K., and Tagawa, S. T. (2013) Prostate-specific membrane antigen-based imaging Urologic Oncology: Seminars and Original Investigations 31, 144-154
20. Chen, Y., Foss, C. A., Byun, Y., Nimmagadda, S., Pullambhatla, M., Fox, J. J., Castanares, M., Lupold, S. E., Babich, J. W., Mease, R. C., and Pomper, M. G. (2008) Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer J. Med. Chem. 51, 7933-43
21. Chen, Y., Dhara, S., Banerjee, S. R., Byun, Y., Pullambhatla, M., Mease, R. C., and Pomper, M. G. (2009) A low molecular weight PSMA-based fluorescent imaging agent for cancer Biochem. Biophys. Res. Commun. 390, 624-9
22. Banerjee, S. R., Pullambhatla, M., Byun, Y., Nimmagadda, S., Foss, C. A., Green, G., Fox, J. J., Lupold, S. E., Mease, R. C., and Pomper, M. G. (2011) Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen Angew. Chem., Int. Ed. Engl. 50, 9167-70
23. Hrkach, J., Von Hoff, D., Mukkaram Ali, M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., Low, S., McDonnell, K., Peeke, E., Retnarajan, B., Sabnis, A., Schnipper, E., Song, J. J., Song, Y. H., Summa, J., Tompsett, D., Troiano, G., Van Geen Hoven, T., Wright, J., LoRusso, P., Kantoff, P. W., Bander, N. H., Sweeney, C., Farokhzad, O. C., Langer, R., and Zale, S. (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile Sci. Transl. Med. 4, 128ra39
24. Chang, S. S., O'Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D., and Gaudin, P. B. (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature Clin. Cancer Res. 5, 2674-81
25. Chang, S. S., Reuter, V. E., Heston, W. D., Bander, N. H., Grauer, L. S., and Gaudin, P. B. (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res. 59, 3192-8
26. Wernicke, A. G., Edgar, M. A., Lavi, E., Liu, H., Salerno, P., Bander, N. H., and Gutin, P. H. (2011) Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme Arch. Pathol. Lab. Med. 135, 1486-9
27. Arosio, D., Casagrande, C., and Manzoni, L. (2012) Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles Curr. Med. Chem. 19, 3128-51
28. Goodman, S. L. and Picard, M. (2012) Integrins as therapeutic targets Trends Pharmacol. Sci. 33, 405-12
29. Goel, H. L., Li, J., Kogan, S., and Languino, L. R. (2008) Integrins in prostate cancer progression Endocr. Relat. Cancer 15, 657-64
30. Abdollahi, A., Griggs, D. W., Zieher, H., Roth, A., Lipson, K. E., Saffrich, R., Grone, H. J., Hallahan, D. E., Reisfeld, R. A., Debus, J., Niethammer, A. G., and Huber, P. E. (2005) Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy Clin. Cancer Res. 11, 6270-9
31. Ye, Y. and Chen, X. (2011) Integrin targeting for tumor optical imaging Theranostics 1, 102-26
32. Zheng, D. Q., Woodard, A. S., Fornaro, M., Tallini, G., and Languino, L. R. (1999) Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway Cancer Res. 59, 1655-64
33. Muhlhausen, U., Komljenovic, D., Bretschi, M., Leotta, K., Eisenhut, M., Semmler, W., and Bauerle, T. (2011) A novel PET tracer for the imaging of alphavbeta3 and alphavbeta5 integrins in experimental breast cancer bone metastases Contrast Media Mol. Imaging 6, 413-20
34. Banerjee, S. R., Pullambhatla, M., Shallal, H., Lisok, A., Mease, R. C., and Pomper, M. G. (2011) A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA) Oncotarget 2, 1244-53
35. Yamada, K., Nagashima, I., Hachisu, M., Matsuo, I., and Shimizu, H. (2012) Efficient solid-phase synthesis of cyclic RGD peptides under controlled microwave heating Tetrahedron Lett. 53, 1066-1070
36. Knetsch, P. A., Petrik, M., Rangger, C., Seidel, G., Pietzsch, H. J., Virgolini, I., Decristoforo, C., and Haubner, R. (2013) [(6)(8)Ga]NS(3)-RGD and [(6)(8)Ga] Oxo-DO3A-RGD for imaging alpha(v)beta(3) integrin expression: synthesis, evaluation, and comparison Nucl. Med. Biol. 40, 65-72
37. Atwell, G. J., Baguley, B. C., Wilmanska, D., and Denny, W. A. (1986) Potential antitumor agents. 45. Synthesis, DNA-binding interaction, and biological activity of triacridine derivatives J. Med. Chem. 29, 69-74
38. Cai, W., Zhang, X., Wu, Y., and Chen, X. (2006) A thiol-reactive 18F-labeling agent, N-[2-(4-18Ffluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of avb3 integrin expression J. Nucl. Med. 47, 1172-1180
39. Kumar, C. C., Nie, H., Rogers, C. P., Malkowski, M., Maxwell, E., Catino, J. J., and Armstrong, L. (1997) Biochemical characterization of the binding of echistatin to integrin alphavbeta3 receptor J. Pharmacol. Exp. Ther. 283, 843-53
40. Zhang, J. H., Chung, T. D., and Oldenburg, K. R. (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays J. Biomol. Screen 4, 67-73
41. Wang, W., Wu, Q., Pasuelo, M., McMurray, J. S., and Li, C. (2005) Probing for integrin alpha v beta3 binding of RGD peptides using fluorescence polarization Bioconjugate Chem. 16, 729-34
42. Barinka, C., Byun, Y., Dusich, C. L., Banerjee, S. R., Chen, Y., Castanares, M., Kozikowski, A. P., Mease, R. C., Pomper, M. G., and Lubkowski, J. (2008) Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization J. Med. Chem. 51, 7737-43
43. Xiong, J. P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S. L., and Arnaout, M. A. (2002) Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand Science 296, 151-5
44. Banerjee, S. R., Foss, C. A., Castanares, M., Mease, R. C., Byun, Y., Fox, J. J., Hilton, J., Lupold, S. E., Kozikowski, A. P., and Pomper, M. G. (2008) Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) J. Med. Chem. 51, 4504-17
45. Mlcochova, P., Plechanovova, A., Barinka, C., Mahadevan, D., Saldanha, J. W., Rulisek, L., and Konvalinka, J. (2007) Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis FEBS J. 274, 4731-41
46. Turek-Etienne, T. C., Small, E. C., Soh, S. C., Xin, T. A., Gaitonde, P. V., Barrabee, E. B., Hart, R. F., and Bryant, R. W. (2003) Evaluation of fluorescent compound interference in 4 fluorescence polarization assays: 2 kinases, 1 protease, and 1 phosphatase J. Biomol. Screen 8, 176-84
47. Mammen, M., Choi, S.-K., and Whitesides, G. M. (1998) Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors Angew. Chem., Int. Ed. 37, 2754-2794
48. Fischer, G., Schirrmacher, R., Wangler, B., and Wangler, C. (2013) Radiolabeled heterobivalent peptidic ligands: an approach with high future potential for in vivo imaging and therapy of malignant diseases ChemMedChem 8, 883-90
49. Vauquelin, G. and Charlton, S. J. (2013) Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands Br. J. Pharmacol. 168, 1771-85
50. Kiessling, L. L., Gestwicki, J. E., and Strong, L. E. (2000) Synthetic multivalent ligands in the exploration of cell-surface interactions Curr. Opin. Chem. Biol. 4, 696-703